Prognostic impact of molecular signatures in pancreatic metastatic neuroendocrine tumors (PRODETEN)

#4027

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are an heterogenous group of tumors. This heterogeneity is not explained by the main known prognostic factors (extension, evolution slope and Ki67 index). New molecular biomarkers (ARX, ATRX, DAXX, menin, PDX1) seem promising in non-metastatic PNENs.

Aim(s): PRODETEN is a retrospective multicentric cohort that aims to evaluate the prognostic impact of tumoral expression of those biomarkers evaluated by immunohistochemistry in patients with metastatic PNENs.

Materials and methods: Outcomes were overall survival (OS) and progression-free survival (PFS) under the first line of systemic treatment. In parallel, we used the Super Learner (SL) algorithm to try to stratify patients according to their survival probability.

Conference:

Presenting Author: de Mestier L

Authors: Pokossy Epee J, Cros J, Cadiot G, Do Cao C, Hautefeuille V,

Keywords: pancreas, neuroendocrine, prognostic, ATRX, daxx, arx, pdx1, Super Learner, menin, biomarker,